2,3,4,5-四氢-5-甲基-2-[(5-甲基-1H-咪唑-4-基)甲基]-1H-吡啶并[4,3-b]吲哚-1-酮; 9-甲基-3-(5-甲基-3H-咪唑-4-基甲基)-1,2,3,9-四氢-咔唑-4-一盐酸盐; 2,3,4,5-Tetrahydro-5-methyl-2-((5-methyl-1H-imidazol-4-yl)methyl)-1H-pyrido(4,3-b)indol-1-one; 5-Methyl-2-[(4-methyl-1H-imidazol-5-yl)methyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one; 5-METHYL-2-[(5-METHYL-1H-IMIDAZOL-4-YL)METHYL]-3,4-DIHYDROPYRIDO[4,3-B]INDOL-1-ONE; GR-68755X; GR-68755; GR 68755; GR 68755X; LOTRONEX; GR68755
用途
- 理化性质
盐酸阿洛司琼(alosetron hydrochloride)，化学名为2，3，4，5-四氢-5-甲基-2-[(5-甲基-1H-咪唑-4-基)甲基]-1H-吡啶并[4，3-b]吲哚-l-酮盐酸盐，是英国G1axoSmith Kline公司研制的5-HT3受体拮抗剂。
- 生物活性
Alosetron (GR 68755) 是一种高效、高选择性的 5-HT3 受体 (5-HT3 receptor) 拮抗剂。Alosetron 用于肠易激综合征 (IBS) 的研究。Alosetron 阻断 5HT3 介导的豚鼠肌间和粘膜下神经元的快速去极化，IC50 在 ~55 nM。Alosetron 减轻清醒或麻醉犬直肠扩张的内脏伤害性效应。具有抗炎活性。
- 靶点
5-HT
3
Receptor
- 体内研究
Dexamethasone and Alosetron-treated (1 mg/kg; ip; daily for 6 days) rats exhibits a significant decrease in the diarrhea index, in comparison with TNBS-control group, especially after the initial 2 days of treatment following the induction of colitis.
